Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The pathogenic process in MG can be condensed in three main phases (Fig. 3). In an initial phase, auto-antibodies bind antigenic epitopes located in the AChR subunits, and the number of receptors decreases as a result of receptor cross-linking and an alteration of the receptor turnover. Complement factors attach to the neuromuscular junction, but end-plate destruction does not occur in this phase. Amplitudes of MEPPs and EPPs may be significantly reduced, but because of the large safety factor of the neuromuscular junction, there is no failure of neuromuscular transmission and clinical symptoms are absent. In the following phase, complement-mediated end plate destruction and transient cellular infiltration of the neuromuscular junction take place. Amplitudes of MEPPs and EPPs become markedly reduced, and the EPP quantal content often decreases. At this stage, neuromuscular transmission failure develops, and symptoms of fatigability and weakness occur. This phase approximately corresponds to the acute phase of the EAMG in rats. In the final phase, cellular infiltration disappears and the structure of the end plate degenerates into a highly simplified pattern. MEPPs become extremely reduced in amplitude or undetectable by conventional microelectrode techniques. Mild ongoing denervation and reinnervation takes place. The EPP quantal content becomes quite variable; decreased at end plates reinnervated by small nerve endings or increased at distorted end plates reinnervated by elongated nerve terminals. This phase roughly corresponds to the chronic phase of EAMG.

Original languageEnglish (US)
Pages (from-to)285-303
Number of pages19
JournalNeurologic Clinics
Volume12
Issue number2
StatePublished - 1994

Fingerprint

Lambert-Eaton Myasthenic Syndrome
Neuromuscular Junction
Myasthenia Gravis
Nerve Endings
Microelectrodes
Denervation
Epitopes
Safety
Antibodies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome. / Maselli, Ricardo A.

In: Neurologic Clinics, Vol. 12, No. 2, 1994, p. 285-303.

Research output: Contribution to journalArticle

@article{c5edf537990149b38790d51006d83a25,
title = "Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome",
abstract = "The pathogenic process in MG can be condensed in three main phases (Fig. 3). In an initial phase, auto-antibodies bind antigenic epitopes located in the AChR subunits, and the number of receptors decreases as a result of receptor cross-linking and an alteration of the receptor turnover. Complement factors attach to the neuromuscular junction, but end-plate destruction does not occur in this phase. Amplitudes of MEPPs and EPPs may be significantly reduced, but because of the large safety factor of the neuromuscular junction, there is no failure of neuromuscular transmission and clinical symptoms are absent. In the following phase, complement-mediated end plate destruction and transient cellular infiltration of the neuromuscular junction take place. Amplitudes of MEPPs and EPPs become markedly reduced, and the EPP quantal content often decreases. At this stage, neuromuscular transmission failure develops, and symptoms of fatigability and weakness occur. This phase approximately corresponds to the acute phase of the EAMG in rats. In the final phase, cellular infiltration disappears and the structure of the end plate degenerates into a highly simplified pattern. MEPPs become extremely reduced in amplitude or undetectable by conventional microelectrode techniques. Mild ongoing denervation and reinnervation takes place. The EPP quantal content becomes quite variable; decreased at end plates reinnervated by small nerve endings or increased at distorted end plates reinnervated by elongated nerve terminals. This phase roughly corresponds to the chronic phase of EAMG.",
author = "Maselli, {Ricardo A}",
year = "1994",
language = "English (US)",
volume = "12",
pages = "285--303",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome

AU - Maselli, Ricardo A

PY - 1994

Y1 - 1994

N2 - The pathogenic process in MG can be condensed in three main phases (Fig. 3). In an initial phase, auto-antibodies bind antigenic epitopes located in the AChR subunits, and the number of receptors decreases as a result of receptor cross-linking and an alteration of the receptor turnover. Complement factors attach to the neuromuscular junction, but end-plate destruction does not occur in this phase. Amplitudes of MEPPs and EPPs may be significantly reduced, but because of the large safety factor of the neuromuscular junction, there is no failure of neuromuscular transmission and clinical symptoms are absent. In the following phase, complement-mediated end plate destruction and transient cellular infiltration of the neuromuscular junction take place. Amplitudes of MEPPs and EPPs become markedly reduced, and the EPP quantal content often decreases. At this stage, neuromuscular transmission failure develops, and symptoms of fatigability and weakness occur. This phase approximately corresponds to the acute phase of the EAMG in rats. In the final phase, cellular infiltration disappears and the structure of the end plate degenerates into a highly simplified pattern. MEPPs become extremely reduced in amplitude or undetectable by conventional microelectrode techniques. Mild ongoing denervation and reinnervation takes place. The EPP quantal content becomes quite variable; decreased at end plates reinnervated by small nerve endings or increased at distorted end plates reinnervated by elongated nerve terminals. This phase roughly corresponds to the chronic phase of EAMG.

AB - The pathogenic process in MG can be condensed in three main phases (Fig. 3). In an initial phase, auto-antibodies bind antigenic epitopes located in the AChR subunits, and the number of receptors decreases as a result of receptor cross-linking and an alteration of the receptor turnover. Complement factors attach to the neuromuscular junction, but end-plate destruction does not occur in this phase. Amplitudes of MEPPs and EPPs may be significantly reduced, but because of the large safety factor of the neuromuscular junction, there is no failure of neuromuscular transmission and clinical symptoms are absent. In the following phase, complement-mediated end plate destruction and transient cellular infiltration of the neuromuscular junction take place. Amplitudes of MEPPs and EPPs become markedly reduced, and the EPP quantal content often decreases. At this stage, neuromuscular transmission failure develops, and symptoms of fatigability and weakness occur. This phase approximately corresponds to the acute phase of the EAMG in rats. In the final phase, cellular infiltration disappears and the structure of the end plate degenerates into a highly simplified pattern. MEPPs become extremely reduced in amplitude or undetectable by conventional microelectrode techniques. Mild ongoing denervation and reinnervation takes place. The EPP quantal content becomes quite variable; decreased at end plates reinnervated by small nerve endings or increased at distorted end plates reinnervated by elongated nerve terminals. This phase roughly corresponds to the chronic phase of EAMG.

UR - http://www.scopus.com/inward/record.url?scp=0028224733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028224733&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 285

EP - 303

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 2

ER -